Strategies for designing and monitoring malaria vaccines targeting diverse antigens

Frontiers in Immunology

Volumn 5, Issue JUL, 2014, Pages

  Barry, Alyssa E ^a,b   Arnott, Alicia ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Clinical trials; Diversity; Malaria; Plasmodium falciparum; Plasmodium vivax; Polymorphism; Strain; Vaccine

Indexed keywords

EID: 84905664346     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00359     Document Type: Review

References (153)

1. World Health Organisation. World Malaria Report. Geneva: World Health Organisation (2013).
2. Barry AE, Schultz L, Buckee CO, Reeder JC. Contrasting population structures of the genes encoding ten leading vaccine-candidate antigens of the human malaria parasite, Plasmodium falciparum. PLoS One (2009) 4(12):e8497. doi: 10.1371/journal.pone.0008497
3. Roll Back Malaria Partnership. The Global Malaria Action Plan for a Malaria Free World. Geneva: Roll Back Malaria Partnership (2008).
4. Gething PW, Elyazar IR, Moyes CL, Smith DL, Battle KE, Guerra CA, et al. A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis (2012) 6(9):e1814. doi:10.1371/journal.pntd.0001814
5. Cotter C, Sturrock HJ, Hsiang MS, Liu J, Phillips AA, Hwang J, et al. The changing epidemiology of malaria elimination: new strategies for new challenges. Lancet (2013) 382(9895):900-11. doi:10.1016/S0140-6736(13)60310-4
6. Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, Alonso PL, et al. Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect Dis (2009) 9(9):555-66. doi:10.1016/S1473-3099(09)70177-X
7. World Health Organization. World Malaria Report. Geneva: World Health Organization (2010).
8. Alonso PL, Brown G, Arevalo-Herrera M, Binka F, Chitnis C, Collins F, et al. A research agenda to underpin malaria eradication. PLoS Med (2011) 8(1):e1000406. doi:10.1371/journal.pmed.1000406
9. Takala SL, Plowe CV. Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming "vaccine resistant malaria". Parasite Immunol (2009) 31(9):560-73. doi:10.1111/j.1365-3024.2009.01138.x
10. Riley EM, Stewart VA. Immune mechanisms in malaria: new insights in vaccine development. Nat Med (2013) 19(2):168-78. doi:10.1038/nm.3083
11. Barry AE, Beeson J, Reeder JC, Fowkes F, Arnott A. Using population genetics to guide malaria vaccine design. In: Okwa APO, editor. Malaria Parasites. Rijeka: InTech (2012). p. 231-64.
12. Richards JS, Beeson JG. The future for blood-stage vaccines against malaria. Immunol Cell Biol (2009) 87(5):377-90. doi:10.1038/icb.2009.27
13. Koch R. Dritter Bericht uber die Thatigkeit der Malaria-Expedition. Dtsch Med Wochenschr (1900) 26(17):281-4. doi:10.1055/s-0029-1203823
14. Marsh K, Kinyanjui S. Immune effector mechanisms in malaria. Parasite Immunol (2006) 28(1-2):51-60. doi:10.1111/j.1365-3024.2006.00808.x
15. Doolan DL, Dobano C, Baird JK. Acquired immunity to malaria. Clin Microbiol Rev (2009) 22(1):13-36. doi:10.1128/CMR.00025-08
16. Cohen S, Mc GI, Carrington S. Gamma-globulin and acquired immunity to human malaria. Nature (1961) 192:733-7. doi:10.1038/192733a0
17. Darko CA, Angov E, Collins WE, Bergmann-Leitner ES, Girouard AS, Hitt SL, et al. The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites. Infect Immun (2005) 73(1):287-97. doi:10.1128/IAI.73.1.287-297.2005
18. Dutta S, Sullivan JS, Grady KK, Haynes JD, Komisar J, Batchelor AH, et al. High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model. PLoS One (2009) 4(12):e8138. doi:10.1371/journal.pone.0008138
19. Gentil F, Bargieri DY, Leite JA, Francoso KS, Patricio MB, Espindola NM, et al. A recombinant vaccine based on domain II of Plasmodium vivax apical membrane antigen 1 induces high antibody titres in mice. Vaccine (2010) 28(38):6183-90. doi:10.1016/j.vaccine.2010.07.017
20. Stowers AW, Kennedy MC, Keegan BP, Saul A, Long CA, Miller LH. Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria. Infect Immun (2002) 70(12):6961-7. doi:10.1128/IAI.70.12.6961-6967.2002
21. Schwartz L, Brown GV, Genton B, Moorthy VS. A review of malaria vaccine clinical projects based on the WHO rainbow table. Malar J (2012) 11:11. doi:10.1186/1475-2875-11-11
22. Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A, et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis (2002) 185(6):820-7. doi:10.1086/339342
23. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med (2011) 365(20):1863-75. doi:10.1056/NEJMoa1102287
24. Sirima SB, Cousens S, Druilhe P. Protection against malaria by MSP3 candidate vaccine. N Engl J Med (2011) 365(11):1062-4. doi:10.1056/NEJMc1100670
25. Laurens MB, Thera MA, Coulibaly D, Ouattara A, Kone AK, Guindo AB, et al. Extended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in malian children: 24-month follow-up of a randomized, double-blinded phase 2 trial. PLoS One (2013) 8(11):e79323. doi:10.1371/journal.pone.0079323
26. Clyde DF, Most H, McCarthy VC, Vanderberg JP. Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci (1973) 266(3):169-77. doi:10.1097/00000441-197312000-00001
27. Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, Doolan DL, et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis (2002) 185(8):1155-64. doi:10.1086/339409
28. Nussenzweig V, Nussenzweig RS. Circumsporozoite proteins of malaria parasites. Cell (1985) 42(2):401-3. doi:10.1016/0092-8674(85)90093-5
29. Malaria Vaccine Funders Group. Malaria Vaccine Technology Roadmap. Geneva: World Health Organization (2006).
30. Otieno L. Efficacy of RTS,S/AS01 vaccine candidate against malaria in African infants and children 8 months post-primary vaccination series: a phase III randomized, double-blind controlled trial. Multilateral Initiative on Malaria Pan Africa Conference. Durban (2013).
31. Malaria Vaccine Funders Group. Malaria Vaccine Technology Roadmap. Geneva: World Health Organization (2013).
32. Doolan DL, Aguiar JC, Weiss WR, Sette A, Felgner PL, Regis DP, et al. Utilization of genomic sequence information to develop malaria vaccines. J Exp Biol (2003) 206(Pt 21):3789-802. doi:10.1242/jeb.00615
33. Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, van Gemert GJ, et al. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med (2009) 361(5):468-77. doi:10.1056/NEJMoa0805832
34. Teirlinck AC, McCall MB, Roestenberg M, Scholzen A, Woestenenk R, de Mast Q, et al. Longevity and composition of cellular immune responses following experimental Plasmodium falciparum malaria infection in humans. PLoS Pathog (2011) 7(12):e1002389. doi:10.1371/journal.ppat.1002389
35. Butler NS, Vaughan AM, Harty JT, Kappe SH. Whole parasite vaccination approaches for prevention of malaria infection. Trends Immunol (2012) 33(5):247-54. doi:10.1016/j.it.2012.02.001
36. Hill AV. Vaccines against malaria. Philos Trans R Soc Lond B Biol Sci (2011) 366(1579):2806-14. doi:10.1098/rstb.2011.0091
37. Stanisic DI, Barry AE, Good MF. Escaping the immune system: how the malaria parasite makes vaccine development a challenge. Trends Parasitol (2013) 29(12):612-22. doi:10.1016/j.pt.2013.10.001
38. Singh S, Miura K, Zhou H, Muratova O, Keegan B, Miles A, et al. Immunity to recombinant Plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infect Immun (2006) 74(8):4573-80. doi:10.1128/IAI.01679-05
39. Dent AE, Bergmann-Leitner ES, Wilson DW, Tisch DJ, Kimmel R, Vulule J, et al. Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adults. PLoS One (2008) 3(10):e3557. doi:10.1371/journal.pone.0003557
40. King CL, Michon P, Shakri AR, Marcotty A, Stanisic D, Zimmerman PA, et al. Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection. Proc Natl Acad Sci U S A (2008) 105(24):8363-8. doi:10.1073/pnas.0800371105
41. McCallum FJ, Persson KE, Mugyenyi CK, Fowkes FJ, Simpson JA, Richards JS, et al. Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum. PLoS One (2008) 3(10):e3571. doi:10.1371/journal.pone.0003571
42. Deans JA, Knight AM, Jean WC, Waters AP, Cohen S, Mitchell GH. Vaccination trials in rhesus monkeys with a minor, invariant, Plasmodium knowlesi 66 kD merozoite antigen. Parasite Immunol (1988) 10(5):535-52. doi:10.1111/j.1365-3024.1988.tb00241.x
43. Renia L, Ling IT, Marussig M, Miltgen F, Holder AA, Mazier D. Immunization with a recombinant C-terminal fragment of Plasmodium yoelii merozoite surface protein 1 protects mice against homologous but not heterologous P. yoelii sporozoite challenge. Infect Immun (1997) 65(11):4419-23.
44. Biswas S, Spencer AJ, Forbes EK, Gilbert SC, Holder AA, Hill AV, et al. Recombinant viral-vectored vaccines expressing Plasmodium chabaudi AS apical membrane antigen 1: mechanisms of vaccine-induced blood-stage protection. J Immunol (2012) 188(10):5041-53. doi:10.4049/jimmunol.1101106
45. Lyon JA, Angov E, Fay MP, Sullivan JS, Girourd AS, Robinson SJ, et al. Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses. PLoS One (2008) 3(7):e2830. doi:10.1371/journal.pone.0002830
46. Birkett AJ, Moorthy VS, Loucq C, Chitnis CE, Kaslow DC. Malaria vaccine R&D in the decade of vaccines: breakthroughs, challenges and opportunities. Vaccine (2013) 31(Suppl 2):B233-43. doi:10.1016/j.vaccine.2013.02.040
47. Sultan AA, Thathy V, Nussenzweig V, Menard R. Green fluorescent protein as a marker in Plasmodium berghei transformation. Infect Immun (1999) 67(5):2602-6.
48. The malERA Consultative Group on Vaccines. A research agenda for malaria eradication: vaccines. PLoS Med (2011) 8(1):e1000398. doi:10.1371/journal.pmed.1000398
49. Hviid L. The role of Plasmodium falciparum variant surface antigens in protective immunity and vaccine development. Hum Vaccin (2010) 6(1):84-9. doi:10.4161/hv.6.1.9602
50. World Health Organisation. Malaria Vaccine Rainbow Tables (2013). Available from: http://www.who.int/vaccine_research/links/Rainbow/en/index.html
51. Yoshida N, Nussenzweig RS, Potocnjak P, Nussenzweig V, Aikawa M. Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite. Science (1980) 207(4426):71-3. doi:10.1126/science.6985745
52. Guerin-Marchand C, Druilhe P, Galey B, Londono A, Patarapotikul J, Beaudoin RL, et al. A liver-stage-specific antigen of Plasmodium falciparum characterized by gene cloning. Nature (1987) 329(6135):164-7. doi:10.1038/329164a0
53. Robson KJ, Hall JR, Jennings MW, Harris TJ, Marsh K, Newbold CI, et al. A highly conserved amino-acid sequence in thrombospondin, properdin and in proteins from sporozoites and blood stages of a human malaria parasite. Nature (1988) 335(6185):79-82. doi:10.1038/335079a0
54. Rogers WO, Malik A, Mellouk S, Nakamura K, Rogers MD, Szarfman A, et al. Characterization of Plasmodium falciparum sporozoite surface protein 2. Proc Natl Acad Sci U S A (1992) 89(19):9176-80. doi:10.1073/pnas.89.19.9176
55. Cowan G, Krishna S, Crisanti A, Robson K. Expression of thrombospondin-related anonymous protein in Plasmodium falciparum sporozoites. Lancet (1992) 339(8806):1412-3. doi:10.1016/0140-6736(92)91229-2
56. Holder AA, Blackman MJ, Burghaus PA, Chappel JA, Ling IT, McCallum-Deighton N, et al. A malaria merozoite surface protein (MSP1)-structure, processing and function. Mem Inst Oswaldo Cruz (1992) 87(Suppl 3):37-42. doi:10.1590/S0074-02761992000700004
57. Smythe JA, Coppel RL, Brown GV, Ramasamy R, Kemp DJ, Anders RF. Identification of two integral membrane proteins of Plasmodium falciparum. Proc Natl Acad Sci U S A (1988) 85(14):5195-9. doi:10.1073/pnas.85.14.5195
58. Oeuvray C, Bouharoun-Tayoun H, Gras-Masse H, Bottius E, Kaidoh T, Aikawa M, et al. Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood (1994) 84(5):1594-602.
59. Hodder AN, Crewther PE, Matthew ML, Reid GE, Moritz RL, Simpson RJ, et al. The disulfide bond structure of Plasmodium apical membrane antigen-1. J Biol Chem (1996) 271(46):29446-52. doi:10.1074/jbc.271.46.29446
60. Genton B, Reed ZH. Asexual blood-stage malaria vaccine development: facing the challenges. Curr Opin Infect Dis (2007) 20(5):467-75. doi:10.1097/QCO.0b013e3282dd7a29
61. Fowkes FJ, Richards JS, Simpson JA, Beeson JG. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: a systematic review and meta-analysis. PLoS Med (2010) 7(1):e1000218. doi:10.1371/journal.pmed.1000218
62. Stanisic DI, Richards JS, McCallum FJ, Michon P, King CL, Schoepflin S, et al. Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infect Immun (2009) 77(3):1165-74. doi:10.1128/IAI.01129-08
63. Richards JS, Arumugam TU, Reiling L, Healer J, Hodder AN, Fowkes FJ, et al. Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development. J Immunol (2013) 191(2):795-809. doi:10.4049/jimmunol.1300778
64. Baum J, Chen L, Healer J, Lopaticki S, Boyle M, Triglia T, et al. Reticulocyte-binding protein homologue 5 - an essential adhesin involved in invasion of human erythrocytes by Plasmodium falciparum. Int J Parasitol (2009) 39(3):371-80. doi:10.1016/j.ijpara.2008.10.006
65. Dutta S, Dlugosz LS, Drew DR, Ge X, Ababacar D, Rovira YI, et al. Overcoming antigenic diversity by enhancing the immunogenicity of conserved epitopes on the malaria vaccine candidate apical membrane antigen-1. PLoS Pathog (2013) 9(12):e1003840. doi:10.1371/journal.ppat.1003840
66. Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Ouattara A, Kone AK, et al. A field trial to assess a blood-stage malaria vaccine. N Engl J Med (2011) 365(11):1004-13. doi:10.1056/NEJMoa1008115
67. Ogutu BR, Apollo OJ, McKinney D, Okoth W, Siangla J, Dubovsky F, et al. Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS One (2009) 4(3):e4708. doi:10.1371/journal.pone.0004708
68. Fowkes FJ, Simpson JA, Beeson JG. Implications of the licensure of a partially efficacious malaria vaccine on evaluating second-generation vaccines. BMC Med (2013) 11:232. doi:10.1186/1741-7015-11-232
69. El Sahly HM, Patel SM, Atmar RL, Lanford TA, Dube T, Thompson D, et al. Safety and immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175 region II malaria vaccine in healthy adults living in an area where malaria is not endemic. Clin Vaccine Immunol (2010) 17(10):1552-9. doi:10.1128/CVI.00082-10
70. Douglas AD, Williams AR, Illingworth JJ, Kamuyu G, Biswas S, Goodman AL, et al. The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat Commun (2011) 2:601. doi:10.1038/ncomms1615
71. Crosnier C, Bustamante LY, Bartholdson SJ, Bei AK, Theron M, Uchikawa M, et al. Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum. Nature (2011) 480(7378):534-7. doi:10.1038/nature10606
72. Ntumngia FB, Schloegel J, McHenry AM, Barnes SJ, George MT, Kennedy S, et al. Immunogenicity of single versus mixed allele vaccines of Plasmodium vivax Duffy binding protein region II. Vaccine (2013) 31(40):4382-8. doi:10.1016/j.vaccine.2013.07.002
73. Salanti A, Staalsoe T, Lavstsen T, Jensen AT, Sowa MP, Arnot DE, et al. Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering Plasmodium falciparum involved in pregnancy-associated malaria. Mol Microbiol (2003) 49(1):179-91. doi:10.1046/j.1365-2958.2003.03570.x
74. Rener J, Graves PM, Carter R, Williams JL, Burkot TR. Target antigens of transmission-blocking immunity on gametes of Plasmodium falciparum. J Exp Med (1983) 158(3):976-81. doi:10.1084/jem.158.3.976
75. Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature (2002) 419(6906):498-511. doi:10.1038/nature01097
76. Taechalertpaisarn T, Crosnier C, Bartholdson SJ, Hodder AN, Thompson J, Bustamante LY, et al. Biochemical and functional analysis of two Plasmodium falciparum blood-stage 6-cys proteins: P12 and P41. PLoS One (2012) 7(7):e41937. doi:10.1371/journal.pone.0041937
77. Florens L, Washburn MP, Raine JD, Anthony RM, Grainger M, Haynes JD, et al. A proteomic view of the Plasmodium falciparum life cycle. Nature (2002) 419(6906):520-6. doi:10.1038/nature01107
78. Sanders PR, Gilson PR, Cantin GT, Greenbaum DC, Nebl T, Carucci DJ, et al. Distinct protein classes including novel merozoite surface antigens in Raft-like membranes of Plasmodium falciparum. J Biol Chem (2005) 280(48):40169-76. doi:10.1074/jbc.M509631200
79. Doolan DL, Mu Y, Unal B, Sundaresh S, Hirst S, Valdez C, et al. Profiling humoral immune responses to P. falciparum infection with protein microarrays. Proteomics (2008) 8(22):4680-94. doi:10.1002/pmic.200800194
80. Persson KE, Fowkes FJ, McCallum FJ, Gicheru N, Reiling L, Richards JS, et al. Erythrocyte-binding antigens of Plasmodium falciparum are targets of human inhibitory antibodies and function to evade naturally acquired immunity. J Immunol (2013) 191(2):785-94. doi:10.4049/jimmunol.1300444
81. Tetteh KK, Stewart LB, Ochola LI, Amambua-Ngwa A, Thomas AW, Marsh K, et al. Prospective identification of malaria parasite genes under balancing selection. PLoS One (2009) 4(5):e5568. doi:10.1371/journal.pone.0005568
82. Ochola LI, Tetteh KK, Stewart LB, Riitho V, Marsh K, Conway DJ. Allele frequency-based and polymorphism-versus-divergence indices of balancing selection in a new filtered set of polymorphic genes in Plasmodium falciparum. Mol Biol Evol (2010) 27(10):2344-51. doi:10.1093/molbev/msq119
83. Kariuki SK, Njunge J, Muia A, Muluvi G, Gatei W, Ter Kuile F, et al. Effect of malaria transmission reduction by insecticide-treated bed nets (ITNs) on the genetic diversity of Plasmodium falciparum merozoite surface protein (MSP-1) and circumsporozoite (CSP) in Western Kenya. Malar J (2013) 12:295. doi:10.1186/1475-2875-12-295
84. Bailey JA, Mvalo T, Aragam N, Weiser M, Congdon S, Kamwendo D, et al. Use of massively parallel pyrosequencing to evaluate the diversity of and selection on Plasmodium falciparum csp T-cell epitopes in Lilongwe, Malawi. J Infect Dis (2012) 206(4):580-7. doi:10.1093/infdis/jis329
85. Zeeshan M, Alam MT, Vinayak S, Bora H, Tyagi RK, Alam MS, et al. Genetic variation in the Plasmodium falciparum circumsporozoite protein in India and its relevance to RTS,S malaria vaccine. PLoS One (2012) 7(8):e43430. doi:10.1371/journal.pone.0043430
86. Tanabe K, Mita T, Palacpac NM, Arisue N, Tougan T, Kawai S, et al. Within-population genetic diversity of Plasmodium falciparum vaccine candidate antigens reveals geographic distance from a Central sub-Saharan African origin. Vaccine (2013) 31(9):1334-9. doi:10.1016/j.vaccine.2012.12.039
87. Jongwutiwes S, Putaporntip C, Karnchaisri K, Seethamchai S, Hongsrimuang T, Kanbara H. Positive selection on the Plasmodium falciparum sporozoite threonine-asparagine-rich protein: analysis of isolates mainly from low endemic areas. Gene (2008) 410(1):139-46. doi:10.1016/j.gene.2007.12.006
88. Pratt-Riccio LR, Perce-da-Silva Dde S, Lima-Junior Jda C, Theisen M, Santos F, Daniel-Ribeiro CT, et al. Genetic polymorphisms in the glutamate-rich protein of Plasmodium falciparum field isolates from a malaria-endemic area of Brazil. Mem Inst Oswaldo Cruz (2013) 108(4):523-8. doi:10.1590/S0074-02762013000400022
89. Basu M, Maji AK, Mitra M, Sengupta S. Natural selection and population genetic structure of domain-I of Plasmodium falciparum apical membrane antigen-1 in India. Infect Genet Evol (2013) 18:247-56. doi:10.1016/j.meegid.2013.05.015
90. Mehrizi AA, Sepehri M, Karimi F, Djadid ND, Zakeri S. Population genetics, sequence diversity and selection in the gene encoding the Plasmodium falciparum apical membrane antigen 1 in clinical isolates from the south-east of Iran. Infect Genet Evol (2013) 17:51-61. doi:10.1016/j.meegid.2013.03.042
91. Osier FH, Weedall GD, Verra F, Murungi L, Tetteh KK, Bull P, et al. Allelic diversity and naturally acquired allele-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 in Kenya. Infect Immun (2010) 78(11):4625-33. doi:10.1128/IAI.00576-10
92. Ouattara A, Mu J, Takala-Harrison S, Saye R, Sagara I, Dicko A, et al. Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine. Malar J (2010) 9:175. doi:10.1186/1475-2875-9-175
93. Simpalipan P, Pattaradilokrat S, Siripoon N, Seugorn A, Kaewthamasorn M, Butcher RD, et al. Diversity and population structure of Plasmodium falciparum in Thailand based on the spatial and temporal haplotype patterns of the C-terminal 19-kDa domain of merozoite surface protein-1. Malar J (2014) 13(1):54. doi:10.1186/1475-2875-13-54
94. Pan D, Hu J, Ma Q, Pan W, Li M. Diversity and prevalence of the C-terminal region of Plasmodium falciparum merozoite surface protein 1 in China. Acta Trop (2010) 116(3):200-5. doi:10.1016/j.actatropica.2010.08.004
95. Lopez AC, Ortiz A, Coello J, Sosa-Ochoa W, Torres RE, Banegas EI, et al. Genetic diversity of Plasmodium vivax and Plasmodium falciparum in Honduras. Malar J (2012) 11:391. doi:10.1186/1475-2875-11-391
96. Yuan L, Zhao H, Wu L, Li X, Parker D, Xu S, et al. Plasmodium falciparum populations from northeastern Myanmar display high levels of genetic diversity at multiple antigenic loci. Acta Trop (2013) 125(1):53-9. doi:10.1016/j.actatropica.2012.09.008
97. Kang JM, Moon SU, Kim JY, Cho SH, Lin K, Sohn WM, et al. Genetic polymorphism of merozoite surface protein-1 and merozoite surface protein-2 in Plasmodium falciparum field isolates from Myanmar. Malar J (2010) 9:131. doi:10.1186/1475-2875-9-131
98. Reiling L, Richards JS, Fowkes FJ, Barry AE, Triglia T, Chokejindachai W, et al. Evidence that the erythrocyte invasion ligand PfRh2 is a target of protective immunity against Plasmodium falciparum malaria. J Immunol (2010) 185(10):6157-67. doi:10.4049/jimmunol.1001555
99. Reiling L, Richards JS, Fowkes FJ, Wilson DW, Chokejindachai W, Barry AE, et al. The Plasmodium falciparum erythrocyte invasion ligand Pfrh4 as a target of functional and protective human antibodies against malaria. PLoS One (2012) 7(9):e45253. doi:10.1371/journal.pone.0045253
100. Bustamante LY, Bartholdson SJ, Crosnier C, Campos MG, Wanaguru M, Nguon C, et al. A full-length recombinant Plasmodium falciparum PfRH5 protein induces inhibitory antibodies that are effective across common PfRH5 genetic variants. Vaccine (2013) 31(2):373-9. doi:10.1016/j.vaccine.2012.10.106
101. Da DF, Dixit S, Sattabonkot J, Mu J, Abate L, Ramineni B, et al. Anti-Pfs25 human plasma reduces transmission of Plasmodium falciparum isolates that have diverse genetic backgrounds. Infect Immun (2013) 81(6):1984-9. doi:10.1128/IAI.00016-13
102. Hommel M, Elliott SR, Soma V, Kelly G, Fowkes FJ, Chesson JM, et al. Evaluation of the antigenic diversity of placenta-binding Plasmodium falciparum variants and the antibody repertoire among pregnant women. Infect Immun (2010) 78(5):1963-78. doi:10.1128/IAI.01365-09
103. Talundzic E, Shah S, Fawole O, Owino S, Moore JM, Peterson DS. Sequence polymorphism, segmental recombination and toggling amino acid residues within the DBL3X domain of the VAR2CSA placental malaria antigen. PLoS One (2012) 7(2):e31565. doi:10.1371/journal.pone.0031565
104. Gnidehou S, Jessen L, Gangnard S, Ermont C, Triqui C, Quiviger M, et al. Insight into antigenic diversity of VAR2CSA-DBL5epsilon domain from multiple Plasmodium falciparum placental isolates. PLoS One (2010) 5(10):e13105. doi:10.1371/journal.pone.0013105
105. Chen DS, Barry AE, Leliwa-Sytek A, Smith TA, Peterson I, Brown SM, et al. A molecular epidemiological study of var gene diversity to characterize the reservoir of Plasmodium falciparum in humans in Africa. PLoS One (2011) 6(2):e16629. doi:10.1371/journal.pone.0016629
106. Tanabe K, Arisue N, Palacpac NM, Yagi M, Tougan T, Honma H, et al. Geographic differentiation of polymorphism in the Plasmodium falciparum malaria vaccine candidate gene SERA5. Vaccine (2012) 30(9):1583-93. doi:10.1016/j.vaccine.2011.12.124
107. Patil A, Orjuela-Sanchez P, da Silva-Nunes M, Ferreira MU. Evolutionary dynamics of the immunodominant repeats of the Plasmodium vivax malaria-vaccine candidate circumsporozoite protein (CSP). Infect Genet Evol (2010) 10(2):298-303. doi:10.1016/j.meegid.2010.01.006
108. Zakeri S, Abouie Mehrizi A, Djadid ND, Snounou G. Circumsporozoite protein gene diversity among temperate and tropical Plasmodium vivax isolates from Iran. Trop Med Int Health (2006) 11(5):729-37. doi:10.1111/j.1365-3156.2006.01613.x
109. Dias S, Wickramarachchi T, Sahabandu I, Escalante AA, Udagama PV. Population genetic structure of the Plasmodium vivax circumsporozoite protein (Pvcsp) in Sri Lanka. Gene (2013) 518(2):381-7. doi:10.1016/j.gene.2013.01.003
110. Nobrega de Sousa T, Carvalho LH, Alves de Brito CF. Worldwide genetic variability of the Duffy binding protein: insights into Plasmodium vivax vaccine development. PLoS One (2011) 6(8):e22944. doi:10.1371/journal.pone.0022944
111. Chenet SM, Tapia LL, Escalante AA, Durand S, Lucas C, Bacon DJ. Genetic diversity and population structure of genes encoding vaccine candidate antigens of Plasmodium vivax. Malar J (2012) 11(1):68. doi:10.1186/1475-2875-11-68
112. Valizadeh V, Zakeri S, Mehrizi AA, Djadid ND. Population genetics and natural selection in the gene encoding the Duffy binding protein II in Iranian Plasmodium vivax wild isolates. Infect Genet Evol (2014) 21:424-35. doi:10.1016/j.meegid.2013.12.012
113. Ju HL, Kang JM, Moon SU, Bahk YY, Cho PY, Sohn WM, et al. Genetic diversity and natural selection of Duffy binding protein of Plasmodium vivax Korean isolates. Acta Trop (2013) 125(1):67-74. doi:10.1016/j.actatropica.2012.09.016
114. Kano FS, Sanchez BA, Sousa TN, Tang ML, Saliba J, Oliveira FM, et al. Plasmodium vivax Duffy binding protein: baseline antibody responses and parasite polymorphisms in a well-consolidated settlement of the Amazon region. Trop Med Int Health (2012) 17(8):989-1000. doi:10.1111/j.1365-3156.2012.03016.x
115. Ju HL, Kang JM, Moon SU, Kim JY, Lee HW, Lin K, et al. Genetic polymorphism and natural selection of Duffy binding protein of Plasmodium vivax Myanmar isolates. Malar J (2012) 11:60. doi:10.1186/1475-2875-11-60
116. Premaratne PH, Aravinda BR, Escalante AA, Udagama PV. Genetic diversity of Plasmodium vivax Duffy binding protein II (PvDBPII) under unstable transmission and low intensity malaria in Sri Lanka. Infect Genet Evol (2011) 11(6):1327-39. doi:10.1016/j.meegid.2011.04.023
117. Collins WE, Jeffery GM, Roberts JM. A retrospective examination of reinfection of humans with Plasmodium vivax. Am J Trop Med Hyg (2004) 70(6):642-4.
118. Jeffery GM. Epidemiological significance of repeated infections with homologous and heterologous strains and species of Plasmodium. Bull World Health Organ (1966) 35(6):873-82.
119. McKenzie FE, Smith DL, O'Meara WP, Riley EM. Strain theory of malaria: the first 50 years. Adv Parasitol (2008) 66:1-46. doi:10.1016/S0065-308X(08)00201-7
120. Bull PC, Lowe BS, Kortok M, Molyneux CS, Newbold CI, Marsh K. Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria. Nat Med (1998) 4(3):358-60. doi:10.1038/nm0398-358
121. Day KP, Marsh K. Naturally acquired immunity to Plasmodium falciparum. Immunol Today (1991) 12(3):A68-71. doi:10.1016/S0167-5699(05)80020-9
122. Bai T, Becker M, Gupta A, Strike P, Murphy VJ, Anders RF, et al. Structure of AMA1 from Plasmodium falciparum reveals a clustering of polymorphisms that surround a conserved hydrophobic pocket. Proc Natl Acad Sci U S A (2005) 102(36):12736-41. doi:10.1073/pnas.0501808102
123. Collins CR, Withers-Martinez C, Hackett F, Blackman MJ. An inhibitory antibody blocks interactions between components of the malarial invasion machinery. PLoS Pathog (2009) 5(1):e1000273. doi:10.1371/journal.ppat.1000273
124. Nielsen MA, Pinto VV, Resende M, Dahlback M, Ditlev SB, Theander TG, et al. Induction of adhesion-inhibitory antibodies against placental Plasmodium falciparum parasites by using single domains of VAR2CSA. Infect Immun (2009) 77(6):2482-7. doi:10.1128/IAI.00159-09
125. Ntumngia FB, King CL, Adams JH. Finding the sweet spots of inhibition: understanding the targets of a functional antibody against Plasmodium vivax Duffy binding protein. Int J Parasitol (2012) 42(12):1055-62. doi:10.1016/j.ijpara.2012.09.006
126. Dutta S, Lee SY, Batchelor AH, Lanar DE. Structural basis of antigenic escape of a malaria vaccine candidate. Proc Natl Acad Sci U S A (2007) 104(30):12488-93. doi:10.1073/pnas.0701464104
127. Takala SL, Coulibaly D, Thera MA, Batchelor AH, Cummings MP, Escalante AA, et al. Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. Sci Transl Med (2009) 1(2):2ra5. doi:10.1126/scitranslmed.3000257
128. Reeder JC, Wapling J, Mueller I, Siba PM, Barry AE. Population genetic analysis of the Plasmodium falciparum 6-cys protein Pf38 in Papua New Guinea reveals domain-specific balancing selection. Malar J (2011) 10:126. doi:10.1186/1475-2875-10-126
129. Arnott A, Mueller I, Ramsland PA, Siba PM, Reeder JC, Barry AE. Global population structure of the genes encoding the malaria vaccine candidate, Plasmodium vivax apical membrane antigen 1 (PvAMA1). PLoS Negl Trop Dis (2013) 7(10):e2506. doi:10.1371/journal.pntd.0002506
130. Taylor RR, Smith DB, Robinson VJ, McBride JS, Riley EM. Human antibody response to Plasmodium falciparum merozoite surface protein 2 is serogroup specific and predominantly of the immunoglobulin G3 subclass. Infect Immun (1995) 63(11):4382-8.
131. Ouattara A, Takala-Harrison S, Thera MA, Coulibaly D, Niangaly A, Saye R, et al. Molecular basis of allele-specific efficacy of a blood-stage malaria vaccine: vaccine development implications. J Infect Dis (2013) 207(3):511-9. doi:10.1093/infdis/jis709
132. Kusi KA, Faber BW, Thomas AW, Remarque EJ. Humoral immune response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad specificity. PLoS One (2009) 4(12):e8110. doi:10.1371/journal.pone.0008110
133. Remarque EJ, Faber BW, Kocken CH, Thomas AW. A diversity- covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits. Infect Immun (2008) 76(6):2660-70. doi:10.1128/IAI.00170-08
134. Faber BW, Younis S, Remarque EJ, Rodriguez Garcia R, Riasat V, Walraven V, et al. Diversity covering AMA1-MSP119 fusion proteins as malaria vaccines. Infect Immun (2013) 81(5):1479-90. doi:10.1128/IAI.01267-12
135. Coley AM, Parisi K, Masciantonio R, Hoeck J, Casey JL, Murphy VJ, et al. The most polymorphic residue on Plasmodium falciparum apical membrane antigen 1 determines binding of an invasion-inhibitory antibody. Infect Immun (2006) 74(5):2628-36. doi:10.1128/IAI.74.5.2628-2636.2006
136. Conway DJ, Cavanagh DR, Tanabe K, Roper C, Mikes ZS, Sakihama N, et al. A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses. Nat Med (2000) 6(6):689-92. doi:10.1038/76272
137. Weedall GD, Conway DJ. Detecting signatures of balancing selection to identify targets of anti-parasite immunity. Trends Parasitol (2010) 26(7):363-9. doi:10.1016/j.pt.2010.04.002
138. Takala SL, Coulibaly D, Thera MA, Dicko A, Smith DL, Guindo AB, et al. Dynamics of polymorphism in a malaria vaccine antigen at a vaccine-testing site in Mali. PLoS Med (2007) 4(3):e93. doi:10.1371/journal.pmed.0040093
139. Anderson TJ, Haubold B, Williams JT, Estrada-Franco JG, Richardson L, Mollinedo R, et al. Microsatellite markers reveal a spectrum of population structures in the malaria parasite Plasmodium falciparum. Mol Biol Evol (2000) 17(10):1467-82. doi:10.1093/oxfordjournals.molbev.a026247
140. Imwong M, Nair S, Pukrittayakamee S, Sudimack D, Williams JT, Mayxay M, et al. Contrasting genetic structure in Plasmodium vivax populations from Asia and South America. Int J Parasitol (2007) 37(8-9):1013-22. doi:10.1016/j.ijpara.2007.02.010
141. Koepfli C, Mueller I, Marfurt J, Goroti M, Sie A, Oa O, et al. Evaluation of Plasmodium vivax genotyping markers for molecular monitoring in clinical trials. J Infect Dis (2009) 199(7):1074-80. doi:10.1086/597303
142. Falk N, Maire N, Sama W, Owusu-Agyei S, Smith T, Beck HP, et al. Comparison of PCR-RFLP and Genescan-based genotyping for analyzing infection dynamics of Plasmodium falciparum. Am J Trop Med Hyg (2006) 74(6):944-50.
143. Betuela I, Rosanas-Urgell A, Kiniboro B, Stanisic DI, Samol L, de Lazzari E, et al. Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age. J Infect Dis (2012) 206(11):1771-80. doi:10.1093/infdis/jis580
144. Barry AE, Leliwa A, Choi M, Nielsen KM, Hartl DL, Day KP. DNA sequence artifacts and the estimation of time to the most recent common ancestor (TMRCA) of Plasmodium falciparum. Mol Biochem Parasitol (2003) 130(2):143-7. doi:10.1016/S0166-6851(03)00164-6
145. Chan ER, Menard D, David PH, Ratsimbasoa A, Kim S, Chim P, et al. Whole genome sequencing of field isolates provides robust characterization of genetic diversity in Plasmodium vivax. PLoS Negl Trop Dis (2012) 6(9):e1811. doi:10.1371/journal.pntd.0001811
146. Duan J, Mu J, Thera MA, Joy D, Kosakovsky Pond SL, Diemert D, et al. Population structure of the genes encoding the polymorphic Plasmodium falciparum apical membrane antigen 1: implications for vaccine design. Proc Natl Acad Sci U S A (2008) 105(22):7857-62. doi:10.1073/pnas.0802328105
147. Excoffier L, Heckel G. Computer programs for population genetics data analysis: a survival guide. Nat Rev Genet (2006) 7(10):745-58. doi:10.1038/nrg1904
148. Tajima F. Statistical method for testing the neutral mutation hypothesis by DNA polymorphism. Genetics (1989) 123(3):585-95.
149. Parobek CM, Bailey JA, Hathaway NJ, Socheat D, Rogers WO, Juliano JJ. Differing patterns of selection and geospatial genetic diversity within two leading Plasmodium vivax candidate vaccine antigens. PLoS Negl Trop Dis (2014) 8(4):e2796. doi:10.1371/journal.pntd.0002796
150. Bruce MC, Galinski MR, Barnwell JW, Donnelly CA, Walmsley M, Alpers MP, et al. Genetic diversity and dynamics of Plasmodium falciparum and P. vivax populations in multiply infected children with asymptomatic malaria infections in Papua New Guinea. Parasitology (2000) 121(Pt 3):257-72. doi:10.1017/S0031182099006356
151. Stanisic DI, Javati S, Kiniboro B, Lin E, Jiang J, Singh B, et al. Naturally acquired immune responses to P. vivax merozoite surface protein 3alpha and merozoite surface protein 9 are associated with reduced risk of P. vivax malaria in young Papua New Guinean children. PLoS Negl Trop Dis (2013) 7(11):e2498. doi:10.1371/journal.pntd.0002498
152. Barnadas C, Kent D, Timinao L, Iga J, Gray LR, Siba P, et al. A new high-throughput method for simultaneous detection of drug resistance associated mutations in Plasmodium vivax dhfr, dhps and mdr1 genes. Malar J (2011) 10:282. doi:10.1186/1475-2875-10-282
153. Fluck C, Schopflin S, Smith T, Genton B, Alpers MP, Beck HP, et al. Effect of the malaria vaccine combination B on merozoite surface antigen 2 diversity. Infect Genet Evol (2007) 7(1):44-51. doi:10.1016/j.meegid.2006.03.006